Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Short-term Investments (2016 - 2025)

Theravance Biopharma has reported Short-term Investments over the past 12 years, most recently at $147.6 million for Q4 2025.

  • Quarterly Short-term Investments rose 191.87% to $147.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $147.6 million through Dec 2025, up 191.87% year-over-year, with the annual reading at $147.6 million for FY2025, 191.87% up from the prior year.
  • Short-term Investments was $147.6 million for Q4 2025 at Theravance Biopharma, up from $2.4 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $147.6 million in Q4 2025 and troughed at $2.4 million in Q3 2025.
  • The 5-year median for Short-term Investments is $58.4 million (2021), against an average of $60.6 million.
  • The largest YoY upside for Short-term Investments was 191.87% in 2025 against a maximum downside of 96.49% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $83.5 million in 2021, then crashed by 64.9% to $29.3 million in 2022, then soared by 114.52% to $62.9 million in 2023, then dropped by 19.61% to $50.6 million in 2024, then surged by 191.87% to $147.6 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Short-term Investments are $147.6 million (Q4 2025), $2.4 million (Q3 2025), and $56.9 million (Q2 2025).